Hong Kong stocks surge | Hengrui Medicine-B (02595.HK) rises more than 11%, company research data showcased at AACR annual meeting, now forming a matrix for RAS targeted therapy.

As per the Zhitong Finance and Economics APP, Junfang Pharmaceuticals-B (02595.HK) surged over 11%, rising by 10.67% to HK$43.78 by the time of publication with a trading volume of HK$78.47 million.